CN108743879A - 抗血栓青春素中药应用 - Google Patents
抗血栓青春素中药应用 Download PDFInfo
- Publication number
- CN108743879A CN108743879A CN201810948364.0A CN201810948364A CN108743879A CN 108743879 A CN108743879 A CN 108743879A CN 201810948364 A CN201810948364 A CN 201810948364A CN 108743879 A CN108743879 A CN 108743879A
- Authority
- CN
- China
- Prior art keywords
- antithrombotic
- extract
- youth
- radix notoginseng
- youth element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 51
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 64
- 239000000843 powder Substances 0.000 claims abstract description 40
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 39
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 39
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 229920001202 Inulin Polymers 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940029339 inulin Drugs 0.000 claims abstract description 25
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 25
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 24
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 24
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 24
- 235000013976 turmeric Nutrition 0.000 claims abstract description 24
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 22
- 235000017276 Salvia Nutrition 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241001072909 Salvia Species 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- 241001092040 Crataegus Species 0.000 claims description 8
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 8
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 8
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 8
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 8
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 8
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 8
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 8
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 8
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 8
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 241001165494 Rhodiola Species 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 8
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 7
- 208000006011 Stroke Diseases 0.000 abstract description 7
- 208000007536 Thrombosis Diseases 0.000 abstract description 7
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 206010039966 Senile dementia Diseases 0.000 abstract description 6
- 239000000654 additive Substances 0.000 abstract description 6
- 230000000996 additive effect Effects 0.000 abstract description 6
- 230000002929 anti-fatigue Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 125000000524 functional group Chemical group 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 230000036995 brain health Effects 0.000 abstract description 5
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 abstract description 5
- 206010021143 Hypoxia Diseases 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 206010002660 Anoxia Diseases 0.000 abstract description 3
- 241000976983 Anoxia Species 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000007953 anoxia Effects 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical group C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- HQARDVLSJLCFBA-UHFFFAOYSA-N 4-[(4-aminophenyl)carbamoyl]-1h-imidazole-5-carboxylic acid Chemical compound C1=CC(N)=CC=C1NC(=O)C1=C(C(O)=O)NC=N1 HQARDVLSJLCFBA-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- NLUAELPZKFJQDY-UHFFFAOYSA-N N(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O Chemical compound N(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O NLUAELPZKFJQDY-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- -1 curcumin Compound Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000009588 inulin clearance Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
本发明公开了抗血栓青春素中药应用,包括以下原料:1‑10%的菊粉、10‑30%的西洋参提取物、5‑20%的三七粉、10‑20%的姜黄提取物、10‑20%的丹参提取物、10‑30%的山楂提取物。本发明为抗血栓青春素中药应用,具有抗血栓、活血化瘀、温经通络、补气抗疲劳、降三高、增加免疫力、改善记忆、防止老年痴呆、增强脑健康、提高缺氧耐受力、预防旅行血栓症、防止脑中风后遗症和防止心脑血管病的作用,是一种天然植物中药材功能团添加剂,应用在食品、保健品和药品中。
Description
技术领域
本发明属于中药技术领域,具体涉及抗血栓青春素中药提取物及其在药品、保健品、食品中的应用,特别涉及一种来源于天然植物中药材的功能团添加剂。
背景技术
随着人们生活节奏的加快、生活的不规律导致了很多人处于亚健康状态,进而造成人们免疫力低下、体力脑力透支,身体的主要器官长期处于超负荷状态,失眠、乏力、无食欲、易疲劳、心悸、抵抗力差、烦躁易怒、经常性感冒、口腔溃疡或便秘等症状。还有当人们出差时需要乘坐飞机,经济舱因为座位狭小,再加上飞行期间久坐,不断吸入重新过滤的干燥空气,而使得血液变得浓稠,因此比较容易产生血栓塞,严重者会引起呼吸困难,甚至是造成中风或死亡。
鉴于以上原因,发明人在多年临床经验总结及专业知识的基础上,筛选出一些中药材的功能团添加剂,用于食品、保健品、药品中,具有抗血栓、活血化瘀、温经通络、补气抗疲劳、降三高、增加免疫力、改善记忆、防止老年痴呆、增强脑健康、提高缺氧耐受力、预防旅行血栓症、脑中风后遗症、心脑血管病的作用。
发明内容
本发明的目的是提供一种抗血栓青春素中药应用,具有抗血栓、活血化瘀、温经通络、补气抗疲劳、降三高、增加免疫力、改善记忆、防止老年痴呆、增强脑健康、提高缺氧耐受力、预防旅行血栓症、防止脑中风后遗症和防止心脑血管病的作用,是一种天然植物中药材功能团添加剂,应用在食品、保健品和药品中。
为实现上述目的,本发明提供了一种抗血栓青春素中药应用,包括以下原料:1-10%的菊粉、10-30%的西洋参提取物、5-20%的三七粉、10-20%的姜黄提取物、10-20%的丹参提取物、10-30%的山楂提取物。
优选的,还包括15-30%的红景天提取物。
优选的,包括1-5%的菊粉、10-20%的西洋参提取物、10-20%的三七粉、10-20%的姜黄提取物、15-30%的红景天提取物、10-20%的丹参提取物、10-30%的山楂提取物。
优选的,包括5%的菊粉、20%的西洋参提取物、20%的三七粉、10%的姜黄提取物、25%的红景天提取物、10%的丹参提取物、10%的山楂提取物。
优选的,3%的菊粉、17%的西洋参提取物、20%的三七粉、17%的姜黄提取物、16%的红景天提取物、15%的丹参提取物、12%的山楂提取物。
优选的,1%的菊粉、29%的西洋参提取物、10%的三七粉、20%的姜黄提取物、15%的红景天提取物、15%的丹参提取物、10%的山楂提取物。
抗血栓青春素中药应用,包括以下步骤:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成5-20%的三七粉;
其次,按照上述处方比例取1-10%的菊粉、10-30%的西洋参提取物、10-20%的丹参提取物、10-30%的山楂提取物、10-20%的姜黄提取物以及15-30%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照比例需要取步骤3中的抗血栓青春素中药提取物加入到食品中或保健品中或药品中或单独使用。
优选的,所述的抗血栓青春素中药提取物应用在药品中时,其质量百分比为10~40%。
优选的,所述的抗血栓青春素中药提取物应用在保健品中时,其质量百分比为5~20%。
优选的,所述的抗血栓青春素中药提取物应用在食品中时,其质量百分比为5~20%。
因此,本发明采用上述技术的抗血栓青春素中药应用,具有抗血栓、活血化瘀、温经通络、补气抗疲劳、降三高、增加免疫力、改善记忆、防止老年痴呆、增强脑健康、提高缺氧耐受力、预防旅行血栓症、防止脑中风后遗症和防止心脑血管病的作用,是一种天然植物中药材功能团添加剂,应用在食品、保健品和药品中。
下面通过实施例,对本发明的技术方案做进一步的详细描述。
具体实施方式
本发明提供了一种抗血栓青春素中药应用,由以下原料制备:包括以下原料:1-10%的菊粉、10-30%的西洋参提取物、5-20%的三七粉、10-20%的姜黄提取物、10-20%的丹参提取物、10-30%的山楂提取物。
作为优选方案,还包括15-30%的红景天提取物。
相应的,抗血栓青春素中药应用,包括以下步骤:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成5-20%的三七粉;
其次,按照上述处方比例取1-10%的菊粉、10-30%的西洋参提取物、10-20%的丹参提取物、10-30%的山楂提取物、10-20%的姜黄提取物以及15-30%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照8%的比例需要取步骤3中的抗血栓青春素中药提取物加入到食品中或保健品中或药品中或单独使用。
作为优选方案,包括1-5%的菊粉、10-20%的西洋参提取物、10-20%的三七粉、10-20%的姜黄提取物、15-30%的红景天提取物、10-20%的丹参提取物、10-30%的山楂提取物。
实施例1
抗血栓青春素中药包括以下成份:5%的菊粉、20%的西洋参提取物、20%的三七粉、10%的姜黄提取物、25%的红景天提取物、10%的丹参提取物、10%的山楂提取物。
其制备步骤如下:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成20%的三七粉;
其次,按照上述处方比例取5%的菊粉、20%的西洋参提取物、10%的丹参提取物、10%的山楂提取物、10%的姜黄提取物以及25%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照8%的比例需要取步骤3中的抗血栓青春素中药提取物加入到食品中,抗血栓青春素中药提取物应用在食品中时,其质量百分比为5~20%。
实施例2
抗血栓青春素中药包括以下成份:3%的菊粉、17%的西洋参提取物、20%的三七粉、17%的姜黄提取物、16%的红景天提取物、15%的丹参提取物、12%的山楂提取物。
其制备步骤如下:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成20%的三七粉;
其次,按照上述处方比例取3%的菊粉、17%的西洋参提取物、15%的丹参提取物、12%的山楂提取物、17%的姜黄提取物以及16%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照12%的比例需要取步骤3中的抗血栓青春素中药提取物加入到药品中,抗血栓青春素中药提取物应用在药品中时,其质量百分比为10~40%,灌成胶囊或与药物辅料制成颗粒剂或丸剂。
实施例3
抗血栓青春素中药应用包括以下成份:1%的菊粉、29%的西洋参提取物、10%的三七粉、20%的姜黄提取物、15%的红景天提取物、15%的丹参提取物、10%的山楂提取物。
其制备步骤如下:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成10%的三七粉;
其次,按照上述处方比例取1%的菊粉、29%的西洋参提取物、15%的丹参提取物、10%的山楂提取物、20%的姜黄提取物以及15%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照5%的比例需要取步骤3中的抗血栓青春素中药提取物加入到保健品中,抗血栓青春素中药提取物应用在保健品中时,其质量百分比为5~20%。
本发明的原理:
红景天提取物是红景天根部的提取物,气香甜、味苦涩。主要成份为红景天苷和甙元酪醇、络塞维,具有增强免疫功能、保护心脑血管及抗癌抗抑郁的功效。红景天提取物可防止在急冻状态下因周围环境压力继发的心脏收缩力下降和有助于稳定收缩性。利用红景天预处理看来可以引发对该类型压力的有益适应性反应。当服用红景天后的小鼠暴露在急冻状态下时,心脏收缩力的下降被防止,而心脏组织的稳定收缩性在灌注期间一直持续出现。
姜黄提取物为姜科植物姜黄干燥根茎的提取物,主要生物活性物质是姜黄素和姜黄酮,具有降血压、降血脂、利胆、抗菌、抗炎和抗氧化等作用。姜黄素一种非常重要的色素化合物,可防止食品中亚油酸自动氧化,并有防癌、抗癌功能,已被作为天然优质的食品色素广泛应用。
菊粉能大大提高Ca2+、Mg2+、Zn2+、Cu2+、Fe2+”等矿物质的吸收,膳食纤维在消化道能结合金属离子。任何菊粉与矿物质复合物在发酵中均被降解,释放出矿物质,因而使金属离子得到有效的吸收。另外,由发酵所产生的酸降低结肠的pH值l-2个单位,使许多矿物质的溶解度/生物有效性(如磷酸钙)大大的提高。而且,研究表明,菊粉清除率,短链脂肪酸,菊粉,特别是丁酸盐能刺激结肠黏膜细胞的生长,提高肠黏膜的吸收能力,菊粉还能提高某段结肠钙对蛋白质的结合。
西洋参中的皂甙可以有效增强中枢神经,达到静心凝神、消除疲劳、增强记忆力等作用,可适用于失眠、烦躁、记忆力衰退及老年痴呆等症状。西洋参可以抗心律失常、抗心肌缺血、抗心肌氧化、强化心肌收缩能力,冠心病患者症状表现为气阴两虚、心慌气短可长期服用西洋参,疗效显著。西洋参的功效还在于可以调节血压,可有效降低暂时性和持久性血压,有助于高血压、心律失常、冠心病、急性心肌梗塞、脑血栓等疾病的恢复。
三七粉的成分和三七主根一样,富含三七皂苷、三七多糖、三七素、黄酮有效成分,具有止血、活血化瘀、消肿定痛、滋补强壮、抗疲劳、耐缺氧、抗衰老、降血脂、降血压、提高机体免疫功能等作用。可用于治疗外伤出血、瘀血、胃出血、尿血等各种内、外出血症;扩张血管,溶解血栓,改善微循环,预防和治疗高血脂、胆固醇增高、冠心病、心绞痛、脑溢血后遗症等心脑血管疾病;脂肪肝、肝纤维化等肝病以及失血、产后、久病等原因导致的体虚症。
生三七对跌打瘀血、外伤出血、产后血晕、吐血、衄血等血症,冠心病、高血脂、高血压等心脑血管疾病有很有的作用;熟三七对身体虚弱、食欲不振、神经衰弱、过度疲劳、失血、贫血等具有较好的效果;同时熟三七粉对手术后的患者和女性痛经等妇科病有很好的效果。
丹参是一种很常见的中药材,有着很强大的活血化瘀功效。对于那些不小心受伤,导致淤血凝聚在体内的人来讲,每日服用丹参泡水,一日三片,连续三天之后,淤血便会由体内消散,然后随之排泄而出。尤其是老年血栓患者,每日少量食用最佳。丹参的功效与作用里面还有延缓衰老的功效,丹参中含有大量的矿物质、有机物质和维生素E,这些物质在人体消化过程中会消除大量的单胺氧化酶,单胺氧化酶最大的作用就是使人体渐渐衰老,一旦适量消除,就可以起到缓解衰老和提高人体细胞活性作用。
山楂有增加心肌收缩力,增加心输出量,减慢心律的作用,山楂提取物及其总黄酮有增加冠脉血流量,降低心肌耗氧量和心肌氧利用率的作用。山楂对心肌营养性血流量有一定的增加作用,山楂对心肌营养性血流量增加作用,可能与扩张冠脉血管床、改善冠脉循环有关。山楂对豚鼠由硫酸异丙肾上腺素所致急性心肌缺血具有保护作用。山楂提取物有预防或减轻异丙肾上腺素引起心肌缺血或坏死作用。同时山楂乙醇提取液有较持久的降压作用。另外山楂的不同提取部分对不同动物造成的各种高脂模型有较肯定的降脂作用,可拮搞高脂饲料引起的血清胆固醇及甘油三酯含量升高。
综上所述,本发明采用上述成份的抗血栓青春素中药应用,具有抗血栓、活血化瘀、温经通络、补气抗疲劳、降三高、增加免疫力、改善记忆、防止老年痴呆、增强脑健康、提高缺氧耐受力、预防旅行血栓症、防止脑中风后遗症和防止心脑血管病的作用,是一种天然植物中药材功能团添加剂,应用在食品、保健品和药品中。
最后应说明的是:以上实施例仅用以说明本发明的技术方案而非对其进行限制,尽管参照较佳实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对本发明的技术方案进行修改或者等同替换,而这些修改或者等同替换亦不能使修改后的技术方案脱离本发明技术方案的精神和范围。
Claims (10)
1.抗血栓青春素中药,其特征在于,包括以下原料:1-10%的菊粉、10-30%的西洋参提取物、5-20%的三七粉、10-20%的姜黄提取物、10-20%的丹参提取物、10-30%的山楂提取物。
2.根据权利要求1所述的抗血栓青春素中药,其特征在于:还包括15-30%的红景天提取物。
3.根据权利要求2所述的抗血栓青春素中药,其特征在于:包括1-5%的菊粉、10-20%的西洋参提取物、10-20%的三七粉、10-20%的姜黄提取物、15-30%的红景天提取物、10-20%的丹参提取物、10-30%的山楂提取物。
4.根据权利要求3所述的抗血栓青春素中药,其特征在于:包括5%的菊粉、20%的西洋参提取物、20%的三七粉、10%的姜黄提取物、25%的红景天提取物、10%的丹参提取物、10%的山楂提取物。
5.根据权利要求3所述的抗血栓青春素中药,其特征在于:3%的菊粉、17%的西洋参提取物、20%的三七粉、17%的姜黄提取物、16%的红景天提取物、15%的丹参提取物、12%的山楂提取物。
6.根据权利要求3所述的抗血栓青春素中药,其特征在于:1%的菊粉、29%的西洋参提取物、10%的三七粉、20%的姜黄提取物、15%的红景天提取物、15%的丹参提取物、10%的山楂提取物。
7.一种如权利要求1-6任一项所述的抗血栓青春素中药的应用,其特征在于,包括以下步骤:
首先,精选三七,分别洗净后用微火烘干、粉碎、过筛制成5-20%的三七粉;
其次,按照上述处方比例取1-10%的菊粉、10-30%的西洋参提取物、10-20%的丹参提取物、10-30%的山楂提取物、10-20%的姜黄提取物以及15-30%的红景天提取物,混合均匀,得到粉末状混合物;
再次,将三七粉与粉末状混合物进行均匀混合得到抗血栓青春素中药提取物;
最后,分别按照比例需要取步骤3中的抗血栓青春素中药提取物加入到食品中或保健品中或药品中或单独使用。
8.根据权利要求7所述的抗血栓青春素中药的应用,其特征在于:所述的抗血栓青春素中药提取物应用在药品中时,其质量百分比为10~40%。
9.根据权利要求7所述的抗血栓青春素中药应用,其特征在于:所述的抗血栓青春素中药提取物应用在保健品中时,其质量百分比为5~20%。
10.根据权利要求7所述的抗血栓青春素中药应用,其特征在于:所述的抗血栓青春素中药提取物应用在食品中时,其质量百分比为5~20%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810948364.0A CN108743879A (zh) | 2018-08-20 | 2018-08-20 | 抗血栓青春素中药应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810948364.0A CN108743879A (zh) | 2018-08-20 | 2018-08-20 | 抗血栓青春素中药应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108743879A true CN108743879A (zh) | 2018-11-06 |
Family
ID=63967254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810948364.0A Pending CN108743879A (zh) | 2018-08-20 | 2018-08-20 | 抗血栓青春素中药应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108743879A (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101297949A (zh) * | 2008-05-15 | 2008-11-05 | 天科仁祥技术(北京)有限责任公司 | 一种预防和治疗高脂血症的中药及其制备方法 |
CN101569672A (zh) * | 2008-04-29 | 2009-11-04 | 潘诚 | 金脑粉 |
CN101623038A (zh) * | 2008-07-08 | 2010-01-13 | 刘泳宏 | 一种天然五色降脂减肥茶饮料及制作方法 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN102450536A (zh) * | 2010-10-28 | 2012-05-16 | 纽威(武汉)生物科技有限公司 | 用来抑制食欲和排毒减肥消脂的组合物 |
CN102771791A (zh) * | 2012-08-13 | 2012-11-14 | 广州白云山和记黄埔中药有限公司 | 一种保健食品及其制备方法及其用途 |
CN103006838A (zh) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | 一种治疗心脑血管疾病的中药组合物 |
CN103251045A (zh) * | 2012-04-23 | 2013-08-21 | 乔德京 | 辅助降血脂保健食品 |
CN103735622A (zh) * | 2014-01-25 | 2014-04-23 | 苏州法莫生物技术有限公司 | 抗原发性高血压药物 |
CN105412817A (zh) * | 2015-12-04 | 2016-03-23 | 四川艾丽碧丝制药有限公司 | 一种红景天复方口服液及其制备方法 |
CN107836620A (zh) * | 2017-11-16 | 2018-03-27 | 天津市农业生物技术研究中心 | 一种养生固体饮料及其制备方法 |
-
2018
- 2018-08-20 CN CN201810948364.0A patent/CN108743879A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569672A (zh) * | 2008-04-29 | 2009-11-04 | 潘诚 | 金脑粉 |
CN101297949A (zh) * | 2008-05-15 | 2008-11-05 | 天科仁祥技术(北京)有限责任公司 | 一种预防和治疗高脂血症的中药及其制备方法 |
CN101623038A (zh) * | 2008-07-08 | 2010-01-13 | 刘泳宏 | 一种天然五色降脂减肥茶饮料及制作方法 |
CN101810336A (zh) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN102450536A (zh) * | 2010-10-28 | 2012-05-16 | 纽威(武汉)生物科技有限公司 | 用来抑制食欲和排毒减肥消脂的组合物 |
CN103251045A (zh) * | 2012-04-23 | 2013-08-21 | 乔德京 | 辅助降血脂保健食品 |
CN102771791A (zh) * | 2012-08-13 | 2012-11-14 | 广州白云山和记黄埔中药有限公司 | 一种保健食品及其制备方法及其用途 |
CN103006838A (zh) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | 一种治疗心脑血管疾病的中药组合物 |
CN103735622A (zh) * | 2014-01-25 | 2014-04-23 | 苏州法莫生物技术有限公司 | 抗原发性高血压药物 |
CN105412817A (zh) * | 2015-12-04 | 2016-03-23 | 四川艾丽碧丝制药有限公司 | 一种红景天复方口服液及其制备方法 |
CN107836620A (zh) * | 2017-11-16 | 2018-03-27 | 天津市农业生物技术研究中心 | 一种养生固体饮料及其制备方法 |
Non-Patent Citations (2)
Title |
---|
周祯祥等: "《临床中药学》", 30 September 2016, 中国中医药出版社 * |
曹劲松等: "《食品营养强化剂》", 31 January 2002, 中国轻工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100981038B1 (ko) | 아토피 및 여드름 치료용 조성물 | |
CN104799146A (zh) | 一种改善亚健康的功能性营养食品组合及其制备方法 | |
CN106562413A (zh) | 一种提高免疫力膏滋及其制备方法 | |
CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
CN102671097A (zh) | 一种内服治疗冠心病的中药组合物 | |
CN110652552A (zh) | 一种伤口愈合配方及制备方法 | |
CN1742971A (zh) | 砂仁山楂冲剂及其制备工艺 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN108743879A (zh) | 抗血栓青春素中药应用 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN1323598A (zh) | 抗疲劳胶囊 | |
CN106822660A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN104522493A (zh) | 治疗冠状动脉粥样硬化的养生粥及制备方法 | |
CN104547432A (zh) | 治疗高血压性心脏病的中药组合物及制备方法 | |
CN108853413A (zh) | 一种具有益气补血功效的药食同源组合物及其制备方法 | |
CN103494194B (zh) | 一种雄蜂参七胶囊及生产工艺 | |
CN102670700A (zh) | 一种清脑醒神的中药保健药物 | |
CN107519261A (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN1251302A (zh) | 一种治疗植物神经紊乱的复方叶绿素中药及其制造方法 | |
CN115487262A (zh) | 一种改善心脑血管、高血压的组合物及其制备方法 | |
CN104435718A (zh) | 快速缓解心肌梗塞的中药喷剂及其制备方法 | |
CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
CN105214001B (zh) | 一种治疗高血压合并冠心病的中药组合物 | |
CN104474306A (zh) | 改善心肌缺血的补气养血茶饮及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181106 |
|
RJ01 | Rejection of invention patent application after publication |